“Our system has a few differentiators,” Frishman tells TechCrunch. “One is the ability to have really dexterous control directly by the physician. They’re controlling the needle, whether it’s positioning, advancing, actuating — it’s like they’re holding it in their hand.”

MDC is specifically targeting biopsies and ablations in its initial offering. The CEO says those minimally invasive procedures are just the start.